AU6704794A - Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna - Google Patents

Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna

Info

Publication number
AU6704794A
AU6704794A AU67047/94A AU6704794A AU6704794A AU 6704794 A AU6704794 A AU 6704794A AU 67047/94 A AU67047/94 A AU 67047/94A AU 6704794 A AU6704794 A AU 6704794A AU 6704794 A AU6704794 A AU 6704794A
Authority
AU
Australia
Prior art keywords
protection
bone marrow
high dose
human
dihydrofolate reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67047/94A
Inventor
Debabrata Banerjee
Joseph R Bertino
Eli Gilboa
Ming-Xia Li
Barry I Schweitzer
Shi-Cheng Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU6704794A publication Critical patent/AU6704794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AU67047/94A 1993-04-13 1994-04-13 Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna Abandoned AU6704794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4928493A 1993-04-13 1993-04-13
US049284 1993-04-13
PCT/US1994/004129 WO1994024277A1 (en) 1993-04-13 1994-04-13 Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna

Publications (1)

Publication Number Publication Date
AU6704794A true AU6704794A (en) 1994-11-08

Family

ID=21959029

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67047/94A Abandoned AU6704794A (en) 1993-04-13 1994-04-13 Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna

Country Status (2)

Country Link
AU (1) AU6704794A (en)
WO (1) WO1994024277A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887467B1 (en) 1996-03-12 2005-05-03 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
DE60034953T2 (en) * 1999-08-19 2008-01-24 Omniscience Pharmaceuticals, Tempe gene cloning
WO2008144912A1 (en) * 2007-05-25 2008-12-04 Université de Montréal Antifolate agent-resistant dihydrofolate reductases
AU2014273490B2 (en) 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
HUE041497T2 (en) 2014-02-14 2019-05-28 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
DK3569619T3 (en) 2014-03-19 2021-06-14 Cellectis Method for producing CD123-specific CAR T cells for cancer immunotherapy
JP2018504144A (en) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ CLL1-specific multi-chain chimeric antigen receptor
JP2018522907A (en) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
AU2018251150A1 (en) 2017-04-13 2019-11-07 Albert-Ludwigs-Universität Freiburg New sequence specific reagents targeting CCR5 in primary hematopoietic cells
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis Engineered immune cells resistant to tumor microoenvironment
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection
AU2018353112A1 (en) 2017-10-19 2020-04-23 Cellectis Targeted gene integration of NK inhibitors genes for improved immune cells therapy
AU2019216269A1 (en) 2018-01-30 2020-05-28 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
EP4081537A1 (en) 2019-12-23 2022-11-02 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
EP4330288A1 (en) 2021-04-30 2024-03-06 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
AU2022277649A1 (en) 2021-05-21 2023-11-30 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
CN117305261B (en) * 2023-11-30 2024-02-23 北京智源人工智能研究院 Dihydrofolate reductase kink and mutant thereof

Also Published As

Publication number Publication date
WO1994024277A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
AU6704794A (en) Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
AU2317897A (en) Calculation of radiation therapy dose using all particle monte carlo transport
AU9102898A (en) Pluripotential bone marrow cell line and methods of using the same
AU3831793A (en) Spinal implant system
AU7265994A (en) Dynamic implanted vertebral orthesis
AU4512193A (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
HUP9902055A3 (en) Medical composition for the treatment of herpes simplex virus and other infectious diseases
ZA9711353B (en) Intramedullary cavity nail for the treatment of fractures of the hip.
AU4693093A (en) Biocompatible surgical implant
HU9800535D0 (en) Use of pyrimidine derivatives for producing pharmaceutical compositions for preventing tumor
AU7287998A (en) Bioabsorbable intermedullary implant systems and methods of use
AU4067697A (en) Therapeutic compositions for treatment of cancer
AU2661095A (en) Orthopedic robot for reduction of long-bone fractures
AU8963698A (en) Prosthesis of the spinal column
AU4092797A (en) Adjustable modular orthopedic implant
HUP9603607A3 (en) Use of triazolidine derivatives for the preparation of pharmaceutical compositions for the treatment and prophylaxis of osteoporosis
AU9016898A (en) Methods and compositions for treatment of restenosis
AU3704800A (en) Co-administration of lucanthone and radiation for treatment of cancer
AUPN289395A0 (en) Intramedullary bone nail
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
HUP0002249A3 (en) Use of pyrimidine and triazine derivatives for producing pharmaceutical compositions useful for treating cancer
EP0716614A4 (en) Treatment of human tumors by genetic transformation of human tumor cells
AU6245898A (en) Injectable formulations for treatment of osteoporotic bone
PL321836A1 (en) Method of reducing the risk of vertebral bone fracture